UPDATE: Jefferies & Company Reiterates Hold Rating, Raises PT on HCP

In a report published Friday, Jefferies & Company reiterated its Hold rating on HCP

, and slightly raised its price target from $45.00 to $46.00. Jefferies noted, “We are updating our estimates for HCP and AMRE following announcements during the NAREIT conference in San Diego, CA. Our price target for HCP also increases to $46 from $45. See our accompanying note entitled ‘Tweets from NAREIT (November 2012 Edition)'.” HCP closed on Thursday at $43.78.